A single endoscopic procedure could help patients with type 2 diabetes to stop taking insulin and still maintain glycemic control, the researchers have said.
A small study found that a procedure inducing cell regeneration in the duodenum when combined with semaglutide allowed patients with type 2 diabetes to come off insulin.
Coverage for continuous glucose monitoring devices is now extended to all beneficiaries who use insulin, even just once daily, and to those with problematic hypoglycemia.
Sanofi said on Thursday it will cut US list prices for its most-prescribed insulin product, Lantus, by 78% starting next year after similar moves by rivals Novo Nordisk and Eli Lilly.